07:00 , Aug 19, 2013 |  BioCentury  |  Product Development

The next wave in ADCs

After about 25 years of development, antibody-drug conjugates have gained acceptance as a validated approach to the targeted killing of cells, with two drugs approved in the past two years. While Seattle Genetics Inc. and...
07:00 , Jul 22, 2013 |  BC Week In Review  |  Company News

ADC Therapeutics, BZL Biologics deal

ADC received exclusive rights to an antibody against prostate-specific membrane antigen ( PSMA ; FOLH1 ; GCPII ) from BZL to treat prostate cancer. ADC plans to combine the antibody with a pyrrolobenzodiazepine (PBD)-based warhead...
07:00 , Jun 18, 2012 |  BC Week In Review  |  Company News

BZL Biologics LLC, ImaginAb deal

The companies added the co-development of a companion imaging agent to a 2009 deal granting ImaginAb a sublicense to BZL's huJ591 mAb. ImaginAb will provide clinical companion diagnostic capabilities to BZL and BZL-partnered prostate-specific membrane...
07:00 , Oct 26, 2009 |  BC Week In Review  |  Company News

BZL Biologics LLC, ImaginAb deal

ImaginAb received a sublicense for BZL's huJ591 for diagnostic imaging. ImaginAb expects to start development of the humanized mAb against prostate-specific membrane antigen ( PSMA ) for diagnostics in 2010. BZL is eligible for undisclosed...
08:00 , Nov 7, 2005 |  BioCentury  |  Strategy

Millennium pipeline

Millennium pipeline Product Description Indication Status Partner Velcade Small molecule dipeptide boronic acid proteasome inhibitor Multiple myeloma (MM); mantle cell lymphoma; follicular non-Hodgkin's lymphoma; non-small cell lung cancer Mkt (MM); Ph II (other cancers) Johnson...
07:00 , Oct 22, 2001 |  BC Week In Review  |  Clinical News

J591 humanized monoclonal antibody: Phase I

Interim results from 2 U.S. Phase I trials of J591 labeled with either 177-Lutetium or 90-Yttrium in 26 patients with metastatic disease who had failed hormone therapy and chemotherapy showed that both radiolabeled antibodies were...
07:00 , Apr 16, 2001 |  BC Week In Review  |  Company News

BZL Biologics L.L.C., Millennium deal

MLNM will use BZL's humanized J591 antibody to develop and commercialize both immunotoxin and radiolabeled antibodies targeting Prostate Specific Membrane Antigen ( PSMA ). MLNM and BZL will jointly develop the antibody and other antibodies...
07:00 , Apr 11, 2001 |  BC Extra  |  Company News

Millennium antibody deal with BZL

MLNM will use BZL Biologics' humanized J591 antibody to develop and commercialize both immunotoxin and radiolabeled antibodies targeting Prostate Specific Membrane Antigen ( PSMA ). MLNM and BZL (New York, N.Y.) will jointly develop the...
08:00 , Oct 30, 2000 |  BC Week In Review  |  Clinical News

huJ591 humanized antibody against PSMA regulatory update

Cornell Research Foundation Inc. (Ithaca, N.Y.) received U.S. Patent No. 6,136,311 covering the use of antibodies against the extracellular domain of prostate specific membrane antigen (PSMA) to treat and diagnose cancer. BZL, which is the...
07:00 , Aug 28, 2000 |  BC Week In Review  |  Clinical News

Monoclonal antibodies against PSMA regulatory update

Cornell University received U.S. patent No. 6,107,090 covering the use of monoclonal antibodies that bind to the extracellular domain of prostate-specific membrane antigen (PSMA), to treat or diagnose prostate cancer. BZL, which has its huJ591...